{"id":"atx-ms-1467","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL6067992","moleculeType":"Small molecule","molecularWeight":"487.40"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ATX-MS-1467 works by inducing tolerance to MAG, a protein that is targeted by autoreactive T cells in multiple sclerosis. This approach aims to reduce inflammation and halt disease progression. By modulating the immune response, ATX-MS-1467 has the potential to provide long-term disease control.","oneSentence":"ATX-MS-1467 is a peptide-based immunotherapy targeting myelin-associated glycoprotein (MAG) to treat multiple sclerosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:29:35.223Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT01973491","phase":"PHASE2","title":"ATX-MS-1467 in Multiple Sclerosis","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2014-02-28","conditions":"Multiple Sclerosis","enrollment":37},{"nctId":"NCT01097668","phase":"PHASE1","title":"ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Apitope Technology (Bristol) Ltd.","startDate":"2010-03","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["M2736","IL-10 Inducer"],"phase":"phase_2","status":"active","brandName":"ATX-MS-1467","genericName":"ATX-MS-1467","companyName":"Apitope Technology (Bristol) Ltd.","companyId":"apitope-technology-bristol-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"ATX-MS-1467 is a small molecule being studied for the treatment of Multiple Sclerosis and Relapsing Remitting Multiple Sclerosis. It is being evaluated in a proof of concept trial to assess its safety.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}